Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects

Cancer Gene Therapy

Volumn 15, Issue 11, 2008, Pages 693-702

  Jin, H T ^a   Youn, J I ^b   Choi, S Y ^a   Seo, S H ^b   Park, S H ^b   Song, M Y ^b   Yang, S H ^a   Sung, Y C ^a,b  

^a POSTECH Biotech Center   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Adenovirus; Cytokine; Interleukin 23

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 23; OVALBUMIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DELIVERY SYSTEM; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; THYMOMA; VACCINATION;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE TRANSFER TECHNIQUES; INTERLEUKIN-12; INTERLEUKIN-23; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS;

ADENOVIRIDAE;

EID: 53549095703     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.41     Document Type: Article

References (51)

1. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204-216.
2. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002; 23: 201-208.
3. Wang J, Murakami T, Hakamata Y, Ajiki T, Jinbu Y, Akasaka Y et al. Gene gun-mediated oral mucosal transfer of interleukin 12 cDNA coupled with an irradiated melanoma vaccine in a hamster model: successful treatment of oral melanoma and distant skin lesion. Cancer Gene Ther 2001; 8: 705-712.
4. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22.
5. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
6. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
7. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708.
8. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531.
9. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003; 171: 600-607.
10. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-465.
11. Chada S, Ramesh R, Mhashilkar AM. Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5: 463-474.
12. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
13. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 2004; 172: 525-531.
14. Ha SJ, Chang J, Song MK, Suh YS, Jin HT, Lee CH et al. Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat Biotechnol 2002; 20: 381-386.
15. Jin HT, Youn JI, Kim HJ, Lee JB, Ha SJ, Koh JS et al. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 2005; 16: 328-338.
16. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001; 167: 5549-5557.
17. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Therapy 2005; 12: 1180-1186.
18. Shimoda K, Tsutsui H, Aoki K, Kato K, Matsuda T, Numata A et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 2002; 99: 2094-2099.
19. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
20. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92: 1684-1688.
21. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-299.
22. Pham-Nguyen KB, Yang W, Saxena R, Thung SN, Woo SL, Chen SH. Role of NK and T cells in IL-12-induced antitumor response against hepatic colon carcinoma. Int J Cancer 1999; 81: 813-819.
23. Roder JC. The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 1979; 123: 2168-2173.
24. Hirschowitz EA, Crystal RG. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases. Am J Respir Cell Mol Biol 1999; 20: 935-941.
25. Grufman P, Karre K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 2000; 30: 1088-1093.
26. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
27. Radeloff B, Laun K, Zirra M, Volz A. Killer immunoglobulin-like receptor expression on single cells: a cautionary note. Immunology 2003; 110: 421-426.
28. Lima M, Almeida J, Montero AG, Teixeira Mdos A, Queiros ML, Santos AH et al. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004; 165: 1117-1127.
29. Kubota A, Kubota S, Lohwasser S, Mager DL, Takei F. Diversity of NK cell receptor repertoire in adult and neonatal mice. J Immunol 1999; 163: 212-216.
30. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
31. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996; 382: 174-177.
32. Yamamoto K, Shibata F, Miyasaka N, Miura O. The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem Biophys Res Commun 2002; 297: 1245-1252.
33. Wang KS, Ritz J, Frank DA. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol 1999; 162: 299-304.
34. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109(Suppl): S121-S131.
35. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, Yamamoto H et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 2003; 10: 771-778.
36. Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003; 105: 820-824.
37. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859.
38. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
39. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002; 51: 409-416.
40. Schneeberger A, Wagner C, Zemann A, Luhrs P, Kutil R, Goos M et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004; 123: 371-379.
41. Kim TW, Hung CF, Juang J, He L, Hardwick JM, Wu TC. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Therapy 2004; 11: 336-342.
42. Pappalardo F, Lollini PL, Castiglione F, Motta S. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics 2005; 21: 2891-2897.
43. Sobol RE. The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 2006; 13: 725-731.
44. Novakovic S, Stegel V, Kopitar A, Ihan A, Novakovic BJ. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 2007; 25: 8241-8256.
45. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007; 67: 1344-1351.
46. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. Future Oncol 2005; 1: 57-66.
47. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004; 53: 879-892.
48. Seya T, Begum NA, Nomura M, Tsuji S, Matsumoto M, Hayashi A et al. Innate immune therapy for cancer. Screen for molecules capable of activating the innate immune system. Adv Exp Med Biol 2000; 465: 229-237.
49. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol 2004; 25: 47-52.
50. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19: 561-569.
51. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000; 34: 1-25.